Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.46 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11102609 | 0.73 | HTR3A (0.54) | L3MBTL1SMN1; SMN2GABRR1HRH4HRH2 | |
| SCHEMBL8528267 | 0.72 | — | — | |
| SCHEMBL10678280 | 0.69 | L3MBTL1 (0.62) | L3MBTL1SMN1; SMN2GABRR1SLC47A1HRH4 | |
| SCHEMBL11049254 | 0.68 | L3MBTL1 (0.51) | L3MBTL1SMN1; SMN2GABRR1SLC47A1HRH4 | |
| SCHEMBL11107349 | 0.68 | GABRR1 (0.41) | L3MBTL1SMN1; SMN2GABRR1SLC47A1HRH4 | |
| SCHEMBL11544506 | 0.67 | L3MBTL1 (0.68) | L3MBTL1SMN1; SMN2GABRR1SLC47A1HRH4 | |
| SCHEMBL11046386 | 0.67 | HTR3A (0.48) | L3MBTL1GABRR1HRH4HRH2HRH1 | |
| SCHEMBL2830891 | 0.66 | — | — | |
| Bromide SCHEMBL11190708 | 0.66 | L3MBTL1 (0.93) | L3MBTL1SMN1; SMN2GABRR1SLC47A1HRH4 | |
| Hydrochloric Acid SCHEMBL11545099 | 0.66 | L3MBTL1 (0.71) | L3MBTL1SMN1; SMN2GABRR1SLC47A1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | claimed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | claimed |
| EP-2094668-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | claimed |
| WO-2008074679-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | claimed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | claimed |
| US-8399463-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | disclosed |
| EP-2094668-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074679-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | L3MBTL1 4877/4885SMN1; SMN2 4392/4885GABRR1 134/4885 |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | L3MBTL1 4877/4885SMN1; SMN2 4392/4885GABRR1 134/4885 |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | L3MBTL1 4877/4885SMN1; SMN2 4392/4885GABRR1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.